Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC

Launched by SWEDISH LUNG CANCER STUDY GROUP · Aug 25, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at whether adding a moderate dose of radiotherapy to standard medical treatments can help patients with Stage IV non-small cell lung cancer (NSCLC). The goal is to see if this combination can reduce the size of the tumor, improve quality of life, and possibly extend survival. Participants will receive their usual chemotherapy along with radiotherapy after three months of treatment, which may also trigger an effect that helps shrink tumors elsewhere in the body.

To be eligible for this trial, participants should be adults aged 65 to 74 with confirmed Stage IV NSCLC who have not received any previous treatment. They should be in reasonably good health, meaning they can perform everyday activities and have stable lung function. Participants must also agree to follow the study's treatment plan and provide written consent. This trial is currently recruiting, and it aims to provide valuable information about improving treatment outcomes for patients with advanced lung cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological or cytological confirmed non-small cell lung cancer (NSCLC)
• • Stage IV disease
• • Previously untreated disease (before first line treatment)
• • No symptomatic brain metastases
• • Performance status (WHO) 0-2
• • FEV1 (forced expiratory volume one second) ≥ 1 L or \>40% of predicted
• • Written informed consent
• • Life expectancy ≥ 12 weeks
• • Platelet count ≥ 100,00/mm3
• • Hemoglobin ≥ 10 g/dl
• • WBC (White blod cells) ≥ 3,000/mm3
• • Kidney function allowing chemotherapy
• • Patients scheduled for standard platinum based chemotherapy, chemo-immunotherapy or immunotherapy
• • Willing and able to comply with study treatment
• Exclusion Criteria:
• • Requirement for daily supplemental oxygen
• • Second primary malignancy within 3 years, except for any of the following which can be included even if diagnosed within the past 3 years: Carcinoma in situ of the cervix, nonmelanoma skin cancer, history of low-grade (Gleason score ≤ 6) localized prostate cancer, definitely treated stage I breast cancer, other malignancy that was diagnosed and definitely treated ≥ 3 years ago with no subsequent evidence of recurrence
• * Concurrent severe and/or uncontrolled medical condition, including any of the following:
• • Angina pectoris
• • Congestive heart failure within the past 3 months, unless LVEF (left ventricular ejection fraction) \> 40%
• • Myocardial infarction within the past 6 months
• • Clinically significant infection
• • Psychiatric illness or social situation that would limit compliance with study requirements
• • EGFR (epidermal growth factor receptor) mutation or ALK (anaplastic lymphoma kinas) - rearrangement detected